Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

June 8, 2023

Study Completion Date

June 8, 2023

Conditions
Glucocorticoid Effect
Interventions
DRUG

Metyrapone 250 mg Oral Tablets

During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0

DRUG

Placebo 250 mg Tablets

During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0

DRUG

Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s

Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8 in a total daily dose of 19.9mg

DRUG

Placebo (0,9% NaCl solution)

Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

Eleonora Seelig

OTHER